e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Assessment and management of immune-mediated interstitial lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone
Ž. Anzulovic (Zagreb, Croatia), M. Antolic (Zagreb, Croatia), A. Ognjenovic (Zagreb, Croatia), S. Cužic (Zagreb, Croatia), I. Glojnaric (Zagreb, Croatia), B. Hrvacic (Zagreb, Croatia)
Source:
International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases
Session:
Assessment and management of immune-mediated interstitial lung diseases
Session type:
Thematic Poster
Number:
4727
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ž. Anzulovic (Zagreb, Croatia), M. Antolic (Zagreb, Croatia), A. Ognjenovic (Zagreb, Croatia), S. Cužic (Zagreb, Croatia), I. Glojnaric (Zagreb, Croatia), B. Hrvacic (Zagreb, Croatia). A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone. 4727
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Optimizing invasive ventilation for SMA type 1 children who are receiving the gene therapy
Related content which might interest you:
PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Olodaterol attenuates bleomycin induced lung fibrosis in mice
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling
Source: Annual Congress 2013 –Novel mechanisms in lung injury
Year: 2013
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
The novel oligonucleotide therapeutics PK-7010 for TGF-ß1 ameliorates bleomycin-induced pulmonary fibrosis in mice
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides
Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair
Year: 2007
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
The attenuating effect of erythropoietin (EPO) on the expression of myeloperoxidase (MPO) in bleomycin-induced pulmonary fibrosis in rats
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
CHIT1 is a novel therapeutic target in idiopathic pulmonary fibrosis (IPF): anti-fibrotic efficacy of OATD-01, a potent and selective chitinase inhibitor in the mouse model of pulmonary fibrosis
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Time course of bleomycin-induced pulmonary fibrosis and the antifibrotic effect of losartan
Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease
Year: 2007
LSC Abstract – A human lung explant model of fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Molecular immunology of the lung
Year: 2016
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept